Digene Agrees To Pay $16M Plus Royalties To Settle Enzo Biochem Patent Suit

Law360, New York (October 14, 2004, 12:00 AM EDT) -- Medical device maker Digene Corp., which markets a DNA-based test for cervical cancer, has agreed to pay Enzo Biochem $16 million, plus guaranteed royalty payments, to settle a patent-infringement suit over a method for detecting infectious viruses.

Under the agreement, Digene will pay Enzo Biochem $16 million, $2 million of which will go toward royalty payments. The company will also pay royalties of at least $2.5 million in the first year and at least $3.5 million in each of the next four years, according to the...
To view the full article, register now.